Clopidogrel and Proton Pump Inhibitors - Tantry, Udaya S.; Kereiakes, Dean J.; Gurbel, Paul A. (JACC. Cardiovascular interventions, 2011)
Keywords: bleeding; Cardiovascular; clopidogrel; cytochromes; drug-drug interactions; omeprazole; platelet reactivity; proton pump inhibitors; single nucleotide polymorphisms; clopidogrel; GIB; omeprazole; FDA; GI; bleeding; CL-AM; ATPase; PPI; platelet reactivity; HPR; ADP; cytochromes; proton pump inhibitors; drug-drug interactions; MACE; MD; PCI; LD; SNPs; VASP-PRI; single nucleotide polymorphisms; MI; DAPT; maintenance dose; single nucleotide polymorphism; myocardial infarction; high on-treatment platelet reactivity; vasodilator stimulated phosphoprotein–platelet reactivity index; adenosine triphosphatase; dual antiplatelet therapy; percutaneous coronary intervention; adenosine diphosphate; clopidogrel active metabolite; U.S. Food and Drug Administration; loading dose; major adverse cardiac event(s); gastrointestinal bleeding; gastrointestinal